415920-33-1

Basic information

• Product Name: 2,6-bis(benzylthio)pyrimidine-4,5-diamine
• Synonyms: 2,6-bis(benzylthio)pyrimidine-4,5-diamine
• CAS NO: 415920-33-1
• Molecular Weight: 354.5
• Mol File: 415920-33-1.mol

Chemical Properties

• CAS DataBase Reference: 2,6-bis(benzylthio)pyrimidine-4,5-diamine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-bis(benzylthio)pyrimidine-4,5-diamine(415920-33-1)
• EPA Substance Registry System: 2,6-bis(benzylthio)pyrimidine-4,5-diamine(415920-33-1)

Safety Data

• Hazardous Substances Data: 415920-33-1(Hazardous Substances Data)

Upstream product

• 100-39-0 benzyl bromide 
• 31295-41-7 4,5-diamino-2,6-dimercaptopyrimidine 

Relevant articles and documents

The discovery of purine-based agents targeting triple-negative breast cancer and the αB-crystallin/VEGF protein–protein interaction

Oestrogen receptor-negative breast cancer, particularly subtypes such as triple-negative breast cancer (TNBC, around 10–15% of cases), are characterised by poor long-term survival, poor response to therapy and early progression to metastasis. Purine-based compounds represent a privileged scaffold in anticancer drug design, with several clinically approved and experimental agents in clinical development comprising a purine core structure. In this study, a series of new purine-based compounds were synthesised; seven of the new analogues were found to significantly reduce the in vitro viability of TNBC cell lines (MDA-MB-231 and MDA-MB-436) with IC50 values of ≤50 μM. In previous work, we have proposed a new concept for targeting angiogenesis driving TNBC progression, by disrupting the protein–protein interaction between the molecular chaperone αB-crystallin (CRYAB) and VEGF. Since previous clinical studies applying anti-VEGF therapy to TNBC patients have met with limited success, we were interested to test our most promising purine analogues against CRYAB/VEGF, using a custom-designed cell-based CRYAB/VEGF165 interaction assay platform. Analogues 4e and 4f significantly reduced the interaction between CRYAB/VEGF165, and compound 4e (100 μM) was also found to decrease the levels of soluble VEGF expressed by MDA-MB-231 cells by 40%. In conclusion, these promising early activity profiles warrant further investigation to validate this concept.

7-amino-2-alkylthiopteridin-4-yl-amines for the treatment of chemokine-related diseases

Pteridine compounds of formula (I) in which R1, R2, R3 and R4 are as specified in the claims, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in t